United States Biotechnology & Medical Research

Aktis Oncology Inc (AKTS)

Track

Track

Aktis Oncology experienced significant insider trading activity recently, with executives offloading over 6.4 million dollars in shares. These sales occurred amid a 36.7 percent decline in stock value over ninety days. No purchases were recorded during this period, preceding the upcoming November earnings report.
Ticker: AKTS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aktis Oncology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Czibere Akos Chief Medical Officer Officer
Transaction date
Planned sale
Price
69.56
Quantity 98,281 +0.8%
Value US$972,213
Czibere Akos Chief Medical Officer Officer
Transaction date
Planned sale
Price
358.11
Quantity 17,227 +12.5%
Value US$3,083,138
Akos Czibere Officer Officer
Transaction date
Proposed sale
Price
305.08
Quantity 20,316
Value US$3,572,896
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
24.56
Quantity 1,350 -100.0%
Value US$33,159
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
24.56
Quantity 3,506 -72.2%
Value US$86,115
KEN HERRMANN Director Non-Executive Director
Transaction date
Proposed sale
Price
24.56
Quantity 4,856
Value US$119,275
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
25.21
Quantity 3,065 -100.0%
Value US$77,259
KEN HERRMANN Director Non-Executive Director
Transaction date
Proposed sale
Price
25.21
Quantity 3,065
Value US$77,259
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
28.75
Quantity 4,200 -100.0%
Value US$120,740
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
27.94
Quantity 30,000 -87.7%
Value US$838,137
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
27.13
Quantity 15,800 -31.6%
Value US$428,681
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
28.71
Quantity 4,371 -100.0%
Value US$125,482
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
27.95
Quantity 30,829 -87.6%
Value US$861,735
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
27.13
Quantity 14,800 -29.6%
Value US$401,484
AKOS CZIBERE Officer Officer
Transaction date
Proposed sale
Price
27.77
Quantity 50,000
Value US$1,388,700
SHULAMIT RON-BIGGER Officer Officer
Transaction date
Proposed sale
Price
27.75
Quantity 50,000
Value US$1,387,560
2.8
Foley Todd Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 232,870 +5.8%
Value US$4,191,660
3.1
GADICKE ANSBERT Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,112,777 +12.2%
Value US$20,029,986
3.1
EcoR1 Capital, LLC Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 144,443 +71.2%
Value US$2,599,974
3.1
EcoR1 Capital, LLC Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 2,077,779 +91.5%
Value US$37,400,022
Vida Ventures II, LLC Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 22,545 +16.7%
Value US$405,810
Vida Ventures II, LLC Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 812,455 +16.7%
Value US$14,624,190
Kim Helen Susan Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 22,545 +16.7%
Value US$405,810
Kim Helen Susan Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 812,455 +16.7%
Value US$14,624,190
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-24 2026-09-23 PlS Planned sale
Czibere Akos

Chief Medical Officer

Officer
98,281 +0.8%
69.56
US$972,213 		98,281 +0.8% 69.56 US$972,213
2026-09-24 2026-09-23 PlS Planned sale
Czibere Akos

Chief Medical Officer

Officer
17,227 +12.5%
358.11
US$3,083,138 		17,227 +12.5% 358.11 US$3,083,138
2026-09-23 2026-09-23 PrS Proposed sale
Akos Czibere

Officer

Officer
20,316
305.08
US$3,572,896 		20,316 305.08 US$3,572,896
2026-07-21 2026-07-20 S Sale
Herrmann Ken
Non-Executive Director
1,350 -100.0%
24.56
US$33,159 		1,350 -100.0% 24.56 US$33,159
2026-07-21 2026-07-20 S Sale
Herrmann Ken
Non-Executive Director
3,506 -72.2%
24.56
US$86,115 		3,506 -72.2% 24.56 US$86,115
2026-07-20 2026-07-20 PrS Proposed sale
KEN HERRMANN

Director

Non-Executive Director
4,856
24.56
US$119,275 		4,856 24.56 US$119,275
2026-07-20 2026-07-17 S Sale
Herrmann Ken
Non-Executive Director
3,065 -100.0%
25.21
US$77,259 		3,065 -100.0% 25.21 US$77,259
2026-07-17 2026-07-17 PrS Proposed sale
KEN HERRMANN

Director

Non-Executive Director
3,065
25.21
US$77,259 		3,065 25.21 US$77,259
2026-07-10 2026-07-08 S Sale
Ron-Bigger Shulamit

Chief Operating Officer

Officer
4,200 -100.0%
28.75
US$120,740 		4,200 -100.0% 28.75 US$120,740
2026-07-10 2026-07-08 S Sale
Ron-Bigger Shulamit

Chief Operating Officer

Officer
30,000 -87.7%
27.94
US$838,137 		30,000 -87.7% 27.94 US$838,137
2026-07-10 2026-07-08 S Sale
Ron-Bigger Shulamit

Chief Operating Officer

Officer
15,800 -31.6%
27.13
US$428,681 		15,800 -31.6% 27.13 US$428,681
2026-07-10 2026-07-08 S Sale
Czibere Akos

Chief Medical Officer

Officer
4,371 -100.0%
28.71
US$125,482 		4,371 -100.0% 28.71 US$125,482
2026-07-10 2026-07-08 S Sale
Czibere Akos

Chief Medical Officer

Officer
30,829 -87.6%
27.95
US$861,735 		30,829 -87.6% 27.95 US$861,735
2026-07-10 2026-07-08 S Sale
Czibere Akos

Chief Medical Officer

Officer
14,800 -29.6%
27.13
US$401,484 		14,800 -29.6% 27.13 US$401,484
2026-07-08 2026-07-08 PrS Proposed sale
AKOS CZIBERE

Officer

Officer
50,000
27.77
US$1,388,700 		50,000 27.77 US$1,388,700
2026-07-08 2026-07-08 PrS Proposed sale
SHULAMIT RON-BIGGER

Officer

Officer
50,000
27.75
US$1,387,560 		50,000 27.75 US$1,387,560
2026-01-14 2026-01-12 B Purchase
2.8
Foley Todd
Non-Executive Director Large shareholder
232,870 +5.8%
18.00
US$4,191,660 		232,870 +5.8% 18.00 US$4,191,660
2026-01-14 2026-01-12 B Purchase
3.1
GADICKE ANSBERT
Large shareholder
1,112,777 +12.2%
18.00
US$20,029,986 		1,112,777 +12.2% 18.00 US$20,029,986
2026-01-14 2026-01-12 B Purchase
3.4
MPM BIOVENTURES 2018, L.P.
Large shareholder
1,112,777 +12.2%
18.00
US$20,029,986 		1,112,777 +12.2% 18.00 US$20,029,986
2026-01-12 2026-01-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director
144,443 +71.2%
18.00
US$2,599,974 		144,443 +71.2% 18.00 US$2,599,974
2026-01-12 2026-01-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director
2,077,779 +91.5%
18.00
US$37,400,022 		2,077,779 +91.5% 18.00 US$37,400,022
2026-01-12 2026-01-12 B Purchase
Vida Ventures II, LLC
Large shareholder
22,545 +16.7%
18.00
US$405,810 		22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase
Vida Ventures II, LLC
Large shareholder
812,455 +16.7%
18.00
US$14,624,190 		812,455 +16.7% 18.00 US$14,624,190
2026-01-12 2026-01-12 B Purchase
Kim Helen Susan
Non-Executive Director Large shareholder
22,545 +16.7%
18.00
US$405,810 		22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase
Kim Helen Susan
Non-Executive Director Large shareholder
812,455 +16.7%
18.00
US$14,624,190 		812,455 +16.7% 18.00 US$14,624,190
Explore more

More insider trading research around Aktis Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America